Heterogeneity, MCID, and missed trials: comments on “efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: A systematic review and meta-analysis”

We read with great interest Singh et al. [1] on Efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in Parkinson's disease (PD): A systematic review and metaanalysis.Efficacy and safety of GLP-1 RAs in PD: A systematic review and meta-analysis.This study was pre-registered with PROSPERO, strictly followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, assessed risk of bias (RoB) using RoB-2, and assessed the quality of evidence using GRADE.A total of 5 randomized controlled trials (RCTs) with a total of 570 participants were included from 1126 studies, providing a broader perspective on GLP-1 RA effects in PD. [2] We acknowledge that the NLY01 trial was included by Singh et al., but the search strategy itself may not have been optimally designed to capture all relevant agents such as dulaglutide, tirzepatide, and others. [